Autism spectrum disorder-like behaviors induced by hyper-glutamatergic NMDA receptor signaling through hypo-serotonergic 5-HT1A receptor signaling in the prefrontal cortex in mice exposed to prenatal valproic acid

被引:0
作者
Kurahashi, Hitomi [1 ]
Kunisawa, Kazuo [1 ,2 ]
Tanaka, Kenji F. [3 ]
Kubota, Hisayoshi [1 ,2 ]
Hasegawa, Masaya [1 ]
Miyachi, Mai [4 ]
Moriya, Yuka [4 ]
Hasegawa, Yoichi [4 ]
Nagai, Taku [2 ]
Saito, Kuniaki [5 ,6 ,7 ]
Nabeshima, Toshitaka [2 ,6 ,7 ]
Mouri, Akihiro [1 ,2 ,7 ]
机构
[1] Fujita Hlth Univ, Dept Regulatory Sci Evaluat & Dev Pharmaceut & Dev, Grad Sch Hlth Sci, Toyoake, Aichi, Japan
[2] Fujita Hlth Univ, Int Ctr Brain Sci ICBS, Toyoake, Aichi, Japan
[3] Keio Univ, Sch Med, Inst Adv Med Res, Div Brain Sci, Tokyo, Japan
[4] Meijo Univ, Fac Pharm, Div Pharmaceut Sci, Nagoya, Aichi, Japan
[5] Fujita Hlth Univ, Grad Sch Hlth Sci, Dept Dis Control & Prevent, Toyoake, Aichi, Japan
[6] Fujita Hlth Univ, Lab Hlth & Med Sci Innovat HMSI, Grad Sch Hlth Sci, Toyoake, Aichi, Japan
[7] Japanese Drug Org Appropriate Use & Res, Toyoake, Aichi, Japan
基金
日本学术振兴会; 日本科学技术振兴机构;
关键词
PLACEBO-CONTROLLED TRIAL; SODIUM VALPROATE; DOUBLE-BLIND; MOUSE; CHILDREN; MODEL; STIMULATION; MANAGEMENT; BUSPIRONE; MEMANTINE;
D O I
10.1038/s41386-024-02004-z
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by repetitive behaviors, social deficits, and cognitive impairments. Maternal use of valproic acid (VPA) during pregnancy is associated with an increased risk of ASD in offspring. The prevailing pathophysiological hypothesis for ASD involves excitation/inhibition (E/I) imbalances and serotonergic dysfunction. Here, we investigated the association between glutamatergic-serotonergic neuronal interactions and ASD-like behaviors in mice exposed to prenatal VPA. Prenatal VPA exposure induced excessive repetitive self-grooming behavior and impaired social behavior and object recognition memory in young adult period. Prenatal VPA mice showed hyper-glutamatergic function (increase in basal extracellular glutamate levels and CaMKII phosphorylation) and hypo-serotonergic function (decrease in 5-hydroxyindoleacetic acid and stimulation-induced serotonin [5-HT] release, but an increase in 5-HT transporter expression) in the prefrontal cortex. Treatment with a low-affinity NMDA receptor antagonist (memantine), a selective 5-HT reuptake inhibitor (fluoxetine), and a 5-HT1A receptor agonist (tandospirone) attenuated both the increase in CaMKII phosphorylation and ASD-like behavior of prenatal VPA mice. Opto-genetic activation of the serotonergic neuronal system attenuated impairments in social behavior and object recognition memory in prenatal VPA mice. WAY-100635-a 5-HT1A receptor antagonist-antagonized the effect of fluoxetine on impaired social behavior and object recognition memory. These results suggest that E/I imbalance and ASD-like behavior are associated with hypo-serotonergic receptor signaling through 5-HT1A receptors in prenatal VPA mice.
引用
收藏
页码:739 / 750
页数:12
相关论文
共 62 条
  • [41] CaMKII regulates the density of central glutamatergic synapses in vivo
    Rongo, C
    Kaplan, JM
    [J]. NATURE, 1999, 402 (6758) : 195 - 199
  • [42] BEHAVIORAL AND MOLECULAR CHANGES IN THE MOUSE IN RESPONSE TO PRENATAL EXPOSURE TO THE ANTI-EPILEPTIC DRUG VALPROIC ACID
    Roullet, F. I.
    Wollaston, L.
    Decatanzaro, D.
    Foster, J. A.
    [J]. NEUROSCIENCE, 2010, 170 (02) : 514 - 522
  • [43] Model of autism: increased ratio of excitation/inhibition in key neural systems
    Rubenstein, JLR
    Merzenich, MM
    [J]. GENES BRAIN AND BEHAVIOR, 2003, 2 (05) : 255 - 267
  • [44] Change in serotonergic modulation contributes to the synaptic imbalance of neuronal circuit at the prefrontal cortex in the 15q11-13 duplication mouse model of autism
    Saitow, Fumihito
    Takumi, Toru
    Suzuki, Hidenori
    [J]. NEUROPHARMACOLOGY, 2020, 165
  • [45] SEROTONIN RECEPTORS - SUBTYPES, FUNCTIONAL-RESPONSES AND THERAPEUTIC RELEVANCE
    SAXENA, PR
    [J]. PHARMACOLOGY & THERAPEUTICS, 1995, 66 (02) : 339 - 368
  • [46] Emerging drugs for the treatment of irritability associated with autism spectrum disorder
    Shamabadi, Ahmad
    Karimi, Hanie
    Arabzadeh Bahri, Razman
    Motavaselian, Mohsen
    Akhondzadeh, Shahin
    [J]. EXPERT OPINION ON EMERGING DRUGS, 2024, 29 (01) : 45 - 56
  • [47] Excitation-inhibition balance as a framework for investigating mechanisms in neuropsychiatric disorders
    Sohal, Vikaas S.
    Rubenstein, John L. R.
    [J]. MOLECULAR PSYCHIATRY, 2019, 24 (09) : 1248 - 1257
  • [48] Neurocognitive Outcomes from Memantine: A Pilot, Double-Blind, Placebo-Controlled Trial in Children with Autism Spectrum Disorder
    Soorya, Latha Valluripalli
    Fogg, Louis
    Ocampo, Edith
    Printen, Madison
    Youngkin, Sarah
    Halpern, Danielle
    Kolevzon, Alexander
    Lee, Soo
    Grodberg, David
    Anagnostou, Evdokia
    [J]. JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2021, 31 (07) : 475 - 484
  • [49] Prenatal exposure to valproic acid enhances synaptic plasticity in the medial prefrontal cortex and fear memories
    Sui, Li
    Chen, Meng
    [J]. BRAIN RESEARCH BULLETIN, 2012, 87 (06) : 556 - 563
  • [50] Decreased Exploratory Activity in a Mouse Model of 15q Duplication Syndrome; Implications for Disturbance of Serotonin Signaling
    Tamada, Kota
    Tomonaga, Shozo
    Hatanaka, Fumiyuki
    Nakai, Nobuhiro
    Takao, Keizo
    Miyakawa, Tsuyoshi
    Nakatani, Jin
    Takumi, Toru
    [J]. PLOS ONE, 2010, 5 (12):